Last reviewed · How we verify
Sham subtenon block
Sham subtenon block is a Small molecule drug developed by King Saud University. It is currently in Phase 3 development for Control of pain and inflammation in the eye.
Sham subtenon block is a procedure that mimics the administration of a local anesthetic to the eye, but does not actually administer any medication.
A sham subtenon block is a procedure used in clinical trials, specifically in the study of subtenon anesthesia for vitreoretinal surgery. The sham subtenon block typically involves the administration of either 2% lidocaine and 0.5% bupivacaine or a placebo, as part of a study to compare the effects of subtenon anesthesia with general anesthesia.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sham subtenon block |
|---|---|
| Sponsor | King Saud University |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
This procedure is used to control pain and inflammation in the eye, and is often used in conjunction with other treatments. The exact mechanism of action is not well understood, but it is thought to involve the release of natural pain-relieving chemicals in the body. By mimicking the administration of a local anesthetic, the procedure can help to reduce pain and inflammation without the need for actual medication.
Approved indications
- Control of pain and inflammation in the eye
Common side effects
- Eye irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sham subtenon block CI brief — competitive landscape report
- Sham subtenon block updates RSS · CI watch RSS
- King Saud University portfolio CI
Frequently asked questions about Sham subtenon block
What is Sham subtenon block?
How does Sham subtenon block work?
What is Sham subtenon block used for?
Who makes Sham subtenon block?
What development phase is Sham subtenon block in?
What are the side effects of Sham subtenon block?
Related
- Manufacturer: King Saud University — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Control of pain and inflammation in the eye
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing